<DOC>
	<DOCNO>NCT00002882</DOCNO>
	<brief_summary>RATIONALE : Interferon alfa may interfere growth cancer cell . Interleukin-2 may stimulate person 's white blood cell kill melanoma cell . It yet know whether interferon alfa plus combination chemotherapy interleukin-2 effective interferon alfa alone treat patient melanoma . PURPOSE : Randomized phase III trial compare effectiveness interferon alfa without combination chemotherapy plus interleukin-2 treating patient melanoma .</brief_summary>
	<brief_title>Interferon Alfa With Without Combination Chemotherapy Plus Interleukin-2 Treating Patients With Melanoma</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy postoperative adjuvant therapy interferon alfa-2b ( IFN-A ) administer subcutaneously without IV induction v concurrent biochemotherapy include cisplatin , vinblastine , DTIC , IFN-A IL-2 melanoma patient regional lymph node metastasis surgically resect . - Determine relative toxic effect associate adjuvant therapy IFN-A concurrent biochemotherapy include cisplatin , vinblastine , DTIC , IFN-A , IL-2 effect quality life . - Determine prognostic value detection melanoma cell peripheral blood use RT/PCR tyrosinase mRNA . OUTLINE : This randomize study . All patient stratify accord prognostic factor . Patients randomly allocate 1 2 treatment option . Treatment 1 us interferon alfa-2b ( IFN-A ) therapy , treatment 2 include adjuvant biochemotherapy . Patients randomize IFN-A stratify randomize one two interferon schedule . - Schedule A : IV IFN-A induction 5 time week 4 week follow subcutaneous IFN-A maintenance 3 time week 48 week . - Schedule B : Subcutaneous IFN-A 3 time week 52 week . Adjuvant biochemotherapy begin immediately registration study . Cisplatin give IV day 1-4 ; vinblastine give IVPB day 1-4 ; dacarbazine ( DTIC ) give IVPB day 1 ; IFN-A give subcutaneously day 1-5 ; IL-2 give continuous infusion total 96 hour day 1-4 . Each course therapy repeat every 21 day 4 course . Patients receive adjuvant radiotherapy start adjuvant systemic therapy within 8 week lymphadenectomy week completion recovery radiotherapy . PROJECTED ACCRUAL : A total 200 patient ( 100 patient arm ) enter .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Skin Neoplasms</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically diagnose malignant melanoma regional lymph node metastases Undergone complete lymph node dissection free residual tumor No great 90 day diagnosis regional lymph node metastases No distant resect intransit metastasis PATIENT CHARACTERISTICS : Age : 10 66 66 70 excellent physical condition Performance status : 02 Life expectancy : At least 12 month Hematopoietic : Hemoglobin great 10 g/dL WBC great 3,000/mm^3 Platelet count great 100,000/mm^3 Hepatic : Bilirubin great 1.2 mg/dL Renal : Creatinine great 1.5 mg/dL Other : No serious intercurrent illness would compromise tolerance therapy long term survival Must able participate follow minimum 5 year No second malignancy except : In situ cervical cancer Basal squamous skin cancer Must able physically emotionally tolerate biochemotherapy No history pulmonary cardiac dysfunction , e.g. , cardiac rhythm disturbance , congestive heart failure , coronary bypass , impaired cardiac ejection fraction PRIOR CONCURRENT THERAPY : Biologic therapy : No prior immunotherapy interferon IL2 No concurrent immunomodulators Chemotherapy : No prior chemotherapy Endocrine therapy : No concurrent steroids Radiotherapy : Prior adjuvant local radiotherapy allow head neck Surgery : No great 8 week definitive surgery lymph node metastases Other : No concurrent nonsteroid antiinflammatory drug , prostaglandin synthetase inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>stage III melanoma</keyword>
</DOC>